BioNTech is progressing BNT327/PM8002, a bispecific antibody, into global clinical trials for first-line small cell lung cancer and non-small cell lung cancer.
BioNTech is advancing its oncology pipeline with multiple Phase 2 and 3 trials, focusing on antibody-drug conjugates (ADCs), mRNA vaccines, and immuno-oncology therapies.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.